| 32.8669 -0.713 (-2.12%) | 08-18 14:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 39.75 | 1-year : | 46.43 |
| Resists | First : | 34.03 | Second : | 39.75 |
| Pivot price | 31.59  |
|||
| Supports | First : | 28.56 |
Second : | 25.18 |
| MAs | MA(5) : | 33.47  |
MA(20) : | 30.65 |
| MA(100) : | 24.47 |
MA(250) : | 28.59 |
|
| MACD | MACD : | 2 |
Signal : | 1.9 |
| %K %D | K(14,3) : | 88.8 |
D(3) : | 92.2 |
| RSI | RSI(14): 66.9 |
|||
| 52-week | High : | 41.72 | Low : | 15.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AZTA ] has closed below upper band by 33.1%. Bollinger Bands are 34.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.62 - 33.75 | 33.75 - 33.87 |
| Low: | 32.41 - 32.58 | 32.58 - 32.72 |
| Close: | 33.29 - 33.56 | 33.56 - 33.8 |
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Fri, 14 Aug 2026
Azenta: Needs To Overcome A Few Hurdles If The Rally Is To Continue (NASDAQ:AZTA) - Seeking Alpha
Tue, 11 Aug 2026
Azenta (AZTA) Is Up 11.5% After Returning To Profit And Raising Revenue Outlook - Has The Bull Case Changed? - simplywall.st
Sat, 08 Aug 2026
Securities Fraud Investigation Into Azenta, Inc. (AZTA) Continues - The National Law Review
Fri, 07 Aug 2026
Azenta, Inc. $AZTA Stake Cut by Quantinno Capital Management LP - MarketBeat
Thu, 06 Aug 2026
Azenta (AZTA) Is Up 6.7% After Raising 2026 Guidance And Completing $50M Buyback – What’s Changed - Yahoo Finance
Thu, 06 Aug 2026
Azenta, Inc. $AZTA Shares Sold by Bank of New York Mellon Corp - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 113.6 (%) |
| Shares Short | 6,030 (K) |
| Shares Short P.Month | 6,290 (K) |
| EPS | -2.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 34.5 |
| Profit Margin | -20.1 % |
| Operating Margin | -2.3 % |
| Return on Assets (ttm) | -0.8 % |
| Return on Equity (ttm) | -7.1 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 5.86 |
| Sales Per Share | 13.31 |
| EBITDA (p.s.) | 0.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 38 (M) |
| Levered Free Cash Flow | 59 (M) |
| PE Ratio | -13.4 |
| PEG Ratio | 0.5 |
| Price to Book value | 0.95 |
| Price to Sales | 2.47 |
| Price to Cash Flow | 39.99 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|